Panarum Corp Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Newark DE US

Primary Industry

Pharmaceuticals

About

Based in Delaware, US, and founded in 2016, Panarum Corp, operates as a pharmaceutical research and development company that offers non-toxic oral polypeptide therapy medications. In February 2021, Panarum SAS raised USD 0.64 million in venture funding from Cygnus Capital. As of 2022, the company is led by its CEO, Milena Batalla. The company offers a formulation platform used in capsules to protect active ingredients and release them in the small intestine. The company uses the patented technology Proteoral®, to produce active medicinal ingredients, and help in the transportation of hormones, monoclonal antibodies, peptides, polysaccharides, and other macromolecules. It provides support for technical transfer to the manufacturing site.

Current Investors

Draper Cygnus

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.panarum.com

Verticals

HealthTech

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.